Cuvitru is a subcutaneous immunoglobulin therapy used to treat primary immunodeficiency (PI), a group of inherited conditions where the immune system doesn’t produce enough antibodies to fight infections. It is FDA-approved for adults and children aged two years and older. Cuvitru works by supplying the protective antibodies your body can’t make on its own, reducing the frequency and severity of infections.
Conditions Cuvitru Treats
Cuvitru is specifically indicated as replacement therapy for primary humoral immunodeficiency. “Humoral” refers to the part of your immune system responsible for producing antibodies, which are proteins that recognize and help destroy bacteria, viruses, and other pathogens. When this arm of the immune system is impaired, you become vulnerable to repeated, sometimes dangerous infections.
The conditions Cuvitru treats include, but are not limited to:
- Common variable immunodeficiency (CVID), the most frequently diagnosed primary immunodeficiency in adults, marked by low antibody levels and recurrent respiratory and gastrointestinal infections.
- X-linked agammaglobulinemia, a genetic condition primarily affecting males where the body produces very few or no antibodies.
- Congenital agammaglobulinemia, a broader category of inherited conditions where antibody production is absent or severely reduced from birth.
- Wiskott-Aldrich syndrome, a rare condition causing immune deficiency alongside low platelet counts and eczema.
- Severe combined immunodeficiencies (SCID), a group of the most serious primary immunodeficiencies affecting multiple parts of the immune system.
If you have one of these conditions, your body either can’t make immunoglobulin G (IgG), the most abundant type of antibody in the bloodstream, or makes far too little of it. Cuvitru replaces what’s missing.
How Cuvitru Works
Cuvitru is a 20% immunoglobulin solution, meaning it contains a high concentration of IgG antibodies sourced from donated human plasma. These antibodies are the same kind a healthy immune system produces naturally. Once infused under your skin, they gradually enter the bloodstream and circulate throughout the body, providing broad protection against a wide range of common bacteria and viruses.
The 20% concentration is significant because it means less fluid is needed per infusion compared to lower-concentration products. In a Canadian real-world study, the median infusion volume was around 30 to 40 milliliters per session, which translates to shorter infusion times and fewer injection sites. The solution is stabilized with glycine, an amino acid that helps keep the antibodies intact without refrigeration during use.
How It Differs From IV Immunoglobulin
Immunoglobulin replacement therapy has traditionally been given intravenously (directly into a vein), typically once every three to four weeks in a clinic or hospital. Cuvitru is delivered subcutaneously, meaning it’s injected into the fatty tissue just beneath the skin, usually in the abdomen, thighs, or upper arms. This distinction matters for daily life.
Subcutaneous infusions can be done at home after proper training, giving you more control over your schedule. They’re also typically given more frequently, often weekly, which keeps antibody levels steadier in the bloodstream rather than creating the peaks and valleys that come with monthly IV infusions. Many people find the subcutaneous approach causes fewer of the systemic side effects (like headaches and fatigue) associated with large IV doses, because smaller amounts of immunoglobulin enter the body at a time.
How Well It Prevents Infections
The FDA approved Cuvitru based on two clinical studies that measured how well it prevented serious bacterial infections, including pneumonia, bacteremia, and bacterial meningitis. In both studies, the annualized rate of serious bacterial infections was extremely low: 0.012 per person per year in one study and 0.022 in the other. For context, the FDA’s threshold for approval requires the rate to stay below 1.0 serious bacterial infection per person per year. Cuvitru came in far under that bar, with both results reaching statistical significance (p < 0.0001).
In practical terms, this means that across the study populations, serious bacterial infections were rare events. Most participants went the entire study period without experiencing one.
What Infusions Are Like
Cuvitru comes in pre-filled vials and is infused using a small needle and portable pump. You insert the needle into the subcutaneous tissue, connect it to the pump, and the infusion runs over a period that varies depending on your dose and flow rate. Many people infuse once a week, though some adjust the frequency to every two weeks or even more often with smaller doses, depending on what works best for their schedule and how their body responds.
The volume per infusion and number of injection sites depends on how much immunoglobulin you need, which is based on your body weight and your antibody levels. Because Cuvitru is a concentrated 20% solution, most people need fewer sites and shorter infusion times than with less concentrated subcutaneous products. Some patients infuse in as few as one or two sites per session.
Your healthcare team will typically start you on Cuvitru in a clinical setting, supervise the first few infusions, and then train you (or a caregiver) to do it at home. The learning curve is generally manageable, and most people become comfortable with the process within a few sessions.
Common Side Effects
The most frequently reported side effects are local reactions at the infusion site: redness, swelling, itching, or mild pain where the needle was inserted. These tend to be mild and improve over time as your body gets used to the infusions. Many people find that site reactions decrease noticeably after the first few months of treatment.
Systemic side effects like headache, fatigue, nausea, and fever can occur but are less common with subcutaneous infusions than with IV immunoglobulin. Serious allergic reactions are rare. If you have a known deficiency in a specific type of antibody called IgA, there is a small risk of a more significant reaction, so this is something your doctor will check before starting treatment.
Who Should Not Use Cuvitru
Cuvitru is not appropriate for everyone. People with a history of severe allergic reactions to immunoglobulin products or any component of Cuvitru should not use it. It is also not approved for children under two years of age, as safety and efficacy have not been established in that age group. Cuvitru is a replacement therapy for primary immunodeficiency specifically and is not indicated for other immune-related conditions, though immunoglobulin therapies in general are sometimes used off-label for other purposes.